コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ence of the chemoattractant formyl-methionyl-leucyl-phenylalanine.
2 ants, such as the peptide N-formyl-methionyl-leucyl-phenylalanine.
3 myristate acetate (PMA) and formyl-methionyl-leucyl-phenylalanine.
4 tase after stimulation with formyl-methionyl-leucyl-phenylalanine.
5 er muscle in response to N-formyl- methionyl-leucyl-phenylalanine.
7 surface of unactivated and formyl methionyl leucyl phenylalanine-activated PMN as determined by indi
9 ses upon stimulation with N-formyl methionyl leucyl phenylalanine and CC chemokine ligand (CCL) 3 (ne
10 multaneously treated with N-formyl-methionyl-leucyl-phenylalanine and IgE plus polyvalent antigen.
11 ogically relevant agents, N-formyl-methionyl-leucyl-phenylalanine and leukotriene B4, by approximatel
13 tants interleukin 8, C5a, N-formyl-methionyl-leucyl-phenylalanine, and interleukin 15, adhesion molec
14 ads, Staphylococcus aureus, formyl-methionyl-leucyl-phenylalanine, and zymosan were reduced by approx
15 activity and adhesiveness of formylmethionyl-leucyl-phenylalanine- and arachidonic acid-stimulated ne
16 -12-myristate-13-acetate, N-formyl-methionyl-leucyl-phenylalanine, arachidonic acid, tumor necrosis f
17 -produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine, are elevated in high-fat diet-indu
19 of the chemotactic peptide formyl-methionyl-leucyl-phenylalanine at 10(-10)-10(-8) M and to the chem
20 CAM-1, and stimulation with formyl-methionyl-leucyl-phenylalanine boosted capture efficiency through
23 ng the transmucosal flux of formyl-methionyl-leucyl-phenylalanine (f-MLP), a ubiquitous neutrophilic
24 neutrophil stimulation with formyl-methionyl-leucyl-phenylalanine, FcgammaR cross-linking, or phospha
25 s significantly increased N-formyl-methionyl-leucyl phenylalanine (fMLF)-stimulated superoxide releas
26 the plasma membrane upon N-formyl-methionyl-leucyl-phenylalanine (fMLF) stimulation and colocalizes
31 PMN chemotactic responses to formylmethionyl-leucyl-phenylalanine (fMLP) and IL-8 were dose-dependent
32 neutrophils, which binds to formyl-methionyl-leucyl-phenylalanine (fMLP) and plays a role in neutroph
33 and elastase) exposed to N-formyl-methionyl-leucyl-phenylalanine (fMLP) and/or multivalent immune co
34 of the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP) caused a dose-dependent (10(
36 I, and did not require an N-formyl-methionyl-leucyl-phenylalanine (fMLP) gradient for transmigration.
37 cells were exposed to an N-formyl-methionyl-leucyl-phenylalanine (FMLP) gradient whose source was pe
38 chemoattractant signal of N-formyl-methionyl-leucyl-phenylalanine (FMLP) in the absence of a spatial
39 his paradigm, we injected N-formyl-methionyl-leucyl-phenylalanine (FMLP) intradermally in guinea pigs
40 e primary chemoattractant N--formylmethionyl-leucyl-phenylalanine (fMLP) is mediated by leukotriene B
42 n secondary activation by N-formyl-methionyl-leucyl-phenylalanine (FMLP) or phorbol myristate acetate
44 ed human neutrophils with N-formyl-methionyl-leucyl-phenylalanine (fMLP) results in biphasic activati
46 followed by treatment with formyl-methionyl-leucyl-phenylalanine (fMLP) stimulates cells in a physio
50 lation of PMNs with 1 muM N-formyl-methionyl-leucyl-phenylalanine (fMLP) triggered earlier and more s
51 -8), formylpeptides (e.g. N-formyl-methionyl-leucyl-phenylalanine (fMLP)), and platelet-activating fa
52 ing N-formylated peptide (N-formyl-methionyl-leucyl-phenylalanine (fMLP)), platelet activating factor
53 coincubated with 0.5 microM formyl-methionyl-leucyl-phenylalanine (fMLP), 1.3 microM 22:6OOH, or 5.0
54 lls permits absorption of N-formyl-methionyl-leucyl-phenylalanine (fMLP), as occurs in hPepT1 express
55 ) and then activated with N-formyl-methionyl-leucyl-phenylalanine (FMLP), C(2)-ceramide (10 microM) c
56 to the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (FMLP), colony stimulating factor-1
57 dition of PMN stimulants, N-formyl-methionyl-leucyl-phenylalanine (FMLP), or phorbol myristate acetat
58 neutrophils were exposed to formyl-methionyl-leucyl-phenylalanine (fMLP), PKCbetaII was rapidly phosp
59 actic bacterial peptide, N-formyl- methionyl-leucyl-phenylalanine (fMLP), was able to specifically at
60 only a modest response to N-formylmethionine-leucyl-phenylalanine (fMLP), we did reveal clear signali
61 CNS, and also reduces the N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced neutrophil respirato
62 examine the mechanism of N-formyl-methionyl-leucyl-phenylalanine (fMLP)-mediated formation of CysLT.
64 ion of FPRwt reconstituted N-formylmethionyl-leucyl-phenylalanine (FMLP)-stimulated extracellular sig
66 polysaccharide (LPS)- and N-formyl-methionyl-leucyl-phenylalanine (FMLP)-stimulated U937 adhesion to
74 e, opsonized zymosan, and N-formyl-methionyl-leucyl-phenylalanine) induce p22(phox) phosphorylation i
75 atelet-activating factor or formyl-methionyl-leucyl-phenylalanine induced beta(2)-integrin-dependent
76 of these compounds inhibit N-formylmethionyl-leucyl-phenylalanine induced spreading of human neutroph
77 bolish the TNF-alpha- and N-formyl-methionyl-leucyl-phenylalanine-induced activation of acetyltransfe
79 quantitative analysis of N-formyl-methionyl-leucyl-phenylalanine-induced increase in binding of (35)
80 icient in spontaneous and N-formyl-methionyl-leucyl-phenylalanine-induced polarization, 0.5 microM pe
81 ine before stimulation with formyl methionyl-leucyl-phenylalanine inhibited A3 receptor expression an
83 ntact cells stimulated with formyl-methionyl-leucyl-phenylalanine, intermediate filament assembly is
84 s activated to secrete with formyl-methionyl-leucyl-phenylalanine, intermediate filaments are phospho
85 peptide receptor agonist (N-formyl-methionyl-leucyl-phenylalanine-lysine; N-For-MLFK) were compared w
86 phils under conditions of N-formyl-methionyl-leucyl-phenylalanine-mediated cPLA(2)alpha activation.
88 h configuration with PMA, N-formyl-methionyl-leucyl-phenylalanine, or anti-IgE greatly enhanced proto
90 stimulated with anti-IgE, N-formyl-methionyl-leucyl-phenylalanine, or phorbol 12-myristate 13-acetate
91 hil activation induced by N-formyl-methionyl-leucyl-phenylalanine, phorbol 12-myristate 13-acetate, o
92 od extension induced with N-formyl-methionyl-leucyl-phenylalanine, platelet activating factor, and le
94 ophil degranulation due to N-formylmethionyl-leucyl-phenylalanine, providing evidence that this inhib
95 without the high-affinity N-formylmethionyl-leucyl-phenylalanine receptor antagonist N-tert-butoxyca
96 were assayed in vitro for N-formyl-methionyl-leucyl-phenylalanine receptor binding and superoxide pro
97 mannose receptor, and the N-formyl-methionyl-leucyl-phenylalanine receptor) did not have demonstrated
99 on and O(2)(-) responses to formyl-methionyl-leucyl-phenylalanine, reflecting the same cellular pheno
103 generation before and after formyl-methionyl-leucyl-phenylalanine stimulation was significantly reduc
104 onic saline-treatment after formyl methionyl-leucyl-phenylalanine-stimulation augmented A3 receptor e
105 e-colony-stimulating factor/formyl-methionyl-leucyl-phenylalanine stimuli, which can induce eicosanoi
106 ha (TNF-alpha) as well as N-formyl-methionyl-leucyl-phenylalanine treatment leads to increased phosph
107 retains coupling between N-formyl-methionyl-leucyl-phenylalanine tripeptide (FMLP) receptor stimulat
108 eness upon stimulation with formyl-methionyl-leucyl phenylalanine was found to identify sputum eosino
109 y the chemoattractant fMLF (formyl methionyl leucyl phenylalanine) was observed by RICM (reflection i
110 by neutrophils, induced by N-formylmethionyl-leucyl-phenylalanine, was strongly inhibited by inhibito
111 , on FPR1 activation with N-formyl-methionyl-leucyl phenylalanine, WDR26 dissociates from FPR1, resul
112 otype N-formylpeptide fMLF (formyl-methionyl-leucyl-phenylalanine) were both absent in FPR-/- mice.
113 also seen in response to N-formyl-methionyl-leucyl-phenylalanine, zymosan-activated serum, or macrop